Sunshine Biopharma Inc (SBFM)

[stervc]

Huge SBFM 8-K of $977 Million-$1.133 Billion Valuation...

This is absolutely a huge 8-K recently filed by SBFM with the SEC of being valued at $977 Million to $1.133 Billion. To Add... the SBFM lead anticancer compound, Adva-27a, was proven effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells. The results were published within the ANTICANCER RESEARCH, Volume 32, Pages 4423-4432 as also confirmed within the recent 8-K link below followed by the PDF version to read directly from the ANTICANCER RESEARCH website:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12142104

http://ar.iiarjournals.org/
http://ar.iiarjournals.org/content/32/10/4423.full.pdf+html


To add... all should read below further details from the same 8-K link above confirming the $977 Million to $1.133 Billion valuation for SBFM:

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12142104
Item 8.01 Other Events

We had previously reported in our Form 10-K for our fiscal year ended December 31, 2016 and Form 10-Q for the three months ended March 31, 2017, that pursuant to terms included in certain Subscription Agreements with us, we had undertaken to obtain a valuation report (the “Report”) on our issued and outstanding shares by an independent valuation firm. To comply with this obligation, on March 9, 2017, we engaged MNP LLP (“MNP”) to provide us with such Report.

On June 22, 2017, MNP issued its Report, which arrived at an estimated en bloc Fair Market Value at March 31, 2017 (the Valuation Date), of our issued and outstanding shares, in the range of $977.0 million to $1,133.0 million.

MNP is one of the largest public accountancy firms in Canada (www.mnp.ca). The Montréal Valuation Practice (the “Practice”) is engaged in the valuation of businesses, business ownership interests, and securities and intangible assets in connection with business combinations, distributions of listed and unlisted securities, private placements, exchanges of shares, corporate and financial reorganizations, going-private transactions, leveraged buy-outs, fair value measurement of assets and liabilities for purchase price allocation and annual impairment testing for financial reporting pursuant to generally-accepted accounting principles both in Canada and the United States. The Practice has performed more than 3,000 valuations of public and private companies throughout Canada and in the United States during the past thirty years. Members of the Practice have also been playing an active role in the Canadian and U.S. professional societies of which they are accredited members, including serving on governing boards and standards-promulgating committees.

MNP is not an insider, associate, or affiliate of our Company or any of our affiliates, associates, or shareholders (collectively, the “Interested Parties”). MNP does not own shares in the Company, nor does it have any agreements, commitments, or undertakings in respect of any future business involving any of the Interested Parties. MNP’s professional fees for services rendered in preparing the Report were not contingent, in whole or in part, on the conclusions reached therein and were based strictly on the professional time expended on the engagement at their standard hourly rates.

http://www.mnp.ca/en


Facts About MNP
http://www.mnp.ca/en/about-mnp-site
Chief Executive Officer: Jason Tuffs, CPA, CA
Head Office: Calgary, Alberta
Total Team Members: 4,100
CPAs: 1,470
Partners: 670
Offices: 60
Established in 1958

v/r
Sterling